Enclomiphene Citrate in Adults 65 and Older: What Patients and Clinicians Need to Know

What Is Enclomiphene Citrate and Why Is It Used Off-Label in Older Men?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It blocks estrogen receptors in the hypothalamus, which reduces negative feedback on gonadotropin-releasing hormone (GnRH), increases LH and FSH secretion, and drives the testes to produce more testosterone. Because the testes remain active, testicular volume and sperm production are largely maintained, a meaningful advantage over exogenous testosterone in men who want to preserve fertility or avoid the suppression of the hypothalamic-pituitary-gonadal (HPG) axis.

The compound was studied by Repros Therapeutics (now Allergan/AbbVie pipeline) in phase III trials for secondary hypogonadism. The FDA issued two complete response letters, in 2013 and 2016, declining approval due to questions about the cardiovascular and polycythemia risk profile of the drug class. No approved NDA exists as of the date of this review. Every clinical use today is therefore off-label.

Why Men Over 65 Are Considered Candidates

Testosterone declines at roughly 1 to 2 percent per year after age 30 in healthy men, with accelerating decline after 60 [1]. The European Male Aging Study (N=3,369) found that late-onset hypogonadism meeting both biochemical and symptomatic criteria affected approximately 2.1 percent of men aged 40 to 79, with prevalence rising steeply after age 70 [2]. Symptoms include fatigue, reduced libido, loss of lean mass, impaired cognition, depressed mood, and reduced bone mineral density.

Many older men have secondary or mixed hypogonadism: their LH and FSH levels are low-normal or inappropriately low relative to depressed testosterone, suggesting a hypothalamic-pituitary contribution. In these patients, a SERM like enclomiphene could theoretically stimulate the axis rather than replace testosterone exogenously.

Enclomiphene vs. Clomiphene in Older Adults

Racemic clomiphene contains roughly 38 percent enclomiphene and 62 percent zuclomiphene. Zuclomiphene is a weak estrogen agonist with a much longer half-life (weeks vs. Days for enclomiphene) and accumulates with repeated dosing, raising estradiol in some patients [3]. Enclomiphene alone produces a cleaner androgenic response with less estrogenic side-effect burden, which matters more in older men who are already at higher baseline estradiol levels relative to testosterone. A 2013 phase II study published in the International Journal of Impotence Research found that enclomiphene 12.5 mg and 25 mg raised morning testosterone more effectively than clomiphene 50 mg at 3 months, with a more favorable LH-to-estradiol ratio [4].

Pharmacokinetics and Age-Related Changes

Enclomiphene is absorbed orally, reaches peak plasma concentration in approximately 2 hours, and is hepatically metabolized via CYP3A4 with biliary excretion. Its half-life is approximately 10 hours, allowing once-daily dosing.

Hepatic and Renal Changes After Age 65

Hepatic blood flow decreases by roughly 35 to 40 percent between age 30 and 75, and CYP3A4 activity can decline by 20 to 40 percent in older adults [5]. These changes may slow enclomiphene clearance, raise steady-state plasma concentrations above those seen in trial populations (which skewed younger), and increase exposure to the drug at standard doses. No dedicated pharmacokinetic study in men over 65 has been published.

Renal clearance also declines with age. Because enclomiphene is primarily hepatically eliminated, renal impairment has limited direct impact on drug clearance. Still, the polypharmacy context of most older patients introduces CYP3A4 inhibitor risk (azole antifungals, diltiazem, certain statins) that could amplify exposure further.

Protein Binding Considerations

Enclomiphene is highly protein-bound. Older adults often have lower albumin levels, particularly those with chronic illness, which could increase free drug fraction and pharmacodynamic effect at a given total plasma concentration. Clinicians prescribing off-label in this age group should start at the lower end of the dose range (12.5 mg daily) and titrate based on 4 to 6-week testosterone levels rather than applying doses from trials of younger men directly.

Evidence Base: What the Clinical Trials Actually Enrolled

The key enclomiphene trials provide the strongest available evidence, but none focused on men aged 65 and older.

ZA-301 and ZA-302 Phase III Trials

The ZA-301 and ZA-302 trials enrolled men aged 18 to 60 with secondary hypogonadism (morning testosterone <300 ng/dL, body mass index 25 to 42 kg/m²). ZA-301 was a 26-week randomized controlled trial comparing enclomiphene 12.5 mg, enclomiphene 25 mg, and placebo. Enclomiphene 25 mg raised mean morning testosterone from approximately 230 ng/dL to 450 ng/dL, while placebo showed no change [6]. LH and FSH rose in parallel, consistent with central HPG stimulation rather than direct gonadal action.

ZA-302 compared enclomiphene against topical testosterone gel (AndroGel 1.62%). Both treatments raised testosterone to similar levels, but only enclomiphene preserved sperm concentration above the lower reference limit (15 million/mL). In the testosterone gel group, sperm concentration fell by more than 50 percent from baseline [7].

Neither trial enrolled men over 60, let alone over 65.

Older Clomiphene Data as a Proxy

Because enclomiphene is the active isomer of clomiphene, clomiphene citrate studies in older men provide partial insight. A retrospective analysis of 125 men with hypogonadism published in BJU International found that clomiphene 25 to 50 mg raised total testosterone from a mean of 215 ng/dL to 479 ng/dL, with 74 percent of men achieving levels above 300 ng/dL [8]. Mean age was 46, but the cohort included men up to 64 years old. Response appeared blunted in men above age 55, consistent with age-related HPG axis desensitization.

A Cochrane review of testosterone therapy in older men found insufficient evidence to quantify long-term cardiovascular or mortality benefit from testosterone replacement in men over 65 [9]. That review focused on exogenous testosterone, not SERMs, but its cautions about this age group apply broadly.

The TRAVERSE Trial and Cardiovascular Context

The TRAVERSE trial (N=5,246, mean age 63.3 years) was a randomized, placebo-controlled study of testosterone replacement in men with hypogonadism and elevated cardiovascular risk. Published in the New England Journal of Medicine in 2023, it found testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median 33 months, but was associated with higher rates of atrial fibrillation (3.5% vs. 2.4%), acute kidney injury, and pulmonary embolism [10]. TRAVERSE enrolled men on exogenous testosterone, not enclomiphene. Still, any agent that raises testosterone in older men with cardiovascular comorbidities should be considered against this safety backdrop.

Dosing Approach for Geriatric Patients: A Clinical Decision Framework

No geriatric-specific dosing guideline exists for enclomiphene. The following framework is drawn from trial data, pharmacokinetic principles, and the prescribing patterns of experienced endocrinologists working in men's health.

Starting Dose and Titration

Start at 12.5 mg orally once daily in the morning. Obtain a baseline morning testosterone (drawn between 7 and 10 a.m.), LH, FSH, estradiol, complete blood count (CBC), PSA, and fasting lipid panel before initiating therapy.

Recheck testosterone, LH, FSH, and estradiol at 4 to 6 weeks. If testosterone remains below 300 ng/dL and estradiol is <40 pg/mL, the dose may be increased to 25 mg daily. In most phase III participants, 25 mg was the effective ceiling dose; higher doses were not studied in published trials.

Monitoring Intervals

After dose stabilization, monitoring every 3 months for the first year is a reasonable interval, then every 6 months if the patient is stable. PSA surveillance follows standard age-appropriate prostate cancer screening guidelines from the American Cancer Society and the U.S. Preventive Services Task Force [11].

Hematocrit should be checked at every visit. The risk of erythrocytosis (hematocrit >54%) is lower with enclomiphene than with exogenous testosterone or intramuscular testosterone cypionate, because endogenous testosterone production is stimulated rather than supraphysiologic levels being imposed. Baseline erythrocytosis is more common in older men, and any upward trend requires a dose reduction or drug hold.

When to Stop

Discontinue enclomiphene if: total testosterone exceeds 700 ng/dL on two consecutive readings, hematocrit exceeds 52% and does not resolve with dose reduction, PSA rises by more than 1.4 ng/mL over any 12-month period, the patient develops symptomatic visual disturbances (rare but documented with clomiphene-class drugs due to retinal SERM effects), or new atrial fibrillation is detected.

Specific Geriatric Safety Concerns

Polycythemia Risk

Older men, especially those with obstructive sleep apnea or chronic obstructive pulmonary disease, are at higher baseline hematocrit. Even modest testosterone elevation can push hematocrit into the thrombotic risk zone. A 2020 retrospective study of 490 men on clomiphene therapy (mean age 49) found erythrocytosis in 4.7 percent, a rate lower than the 12 to 20 percent commonly reported with injectable testosterone therapy [12]. The rate in men over 65 on enclomiphene is not established.

Bone Health Considerations

Testosterone contributes to bone mineral density via aromatization to estradiol. Low testosterone in older men is associated with increased fracture risk [1]. Enclomiphene raises both testosterone and, indirectly, estradiol (because more testosterone is available for peripheral aromatization). In theory, this could benefit bone. No bone density endpoint trial for enclomiphene in men over 65 has been conducted.

Cognitive and Mood Effects

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest prescribing testosterone therapy to men with age-related decline in testosterone only when there is a clear clinical syndrome of hypogonadism with consistent symptoms" [13]. Cognitive symptoms (memory difficulty, poor concentration) are among the recognized symptoms, but trial evidence for benefit is mixed. The Testosterone Trials (TTrials), a set of 7 coordinated RCTs in 788 men aged 65 and older with testosterone <275 ng/dL, found improvements in sexual function and some quality-of-life domains but no significant improvement in cognitive function at 12 months [14]. Because enclomiphene was not used in the TTrials, any extrapolation to cognitive benefit in older men is speculative.

Drug Interactions in Polypharmacy Patients

Men over 65 take a median of 5 prescription medications. Relevant interactions with enclomiphene include:

• CYP3A4 inhibitors (clarithromycin, diltiazem, verapamil, ketoconazole): may raise enclomiphene plasma levels by 30 to 200 percent; start with 6.25 mg or avoid co-administration.
• Warfarin: SERMs can alter the PT/INR via hepatic CYP2C9 competition; INR monitoring should increase to weekly for 4 weeks after starting or stopping enclomiphene.
• Aromatase inhibitors: sometimes co-prescribed to blunt estradiol rise; this combination is not studied in older men and could suppress estradiol below the bone-protective threshold (<20 pg/mL).

Comparing Enclomiphene to Other Options in Older Men

vs. Exogenous Testosterone (TRT)

Testosterone cypionate, enanthate, and topical testosterone are the most common treatments for hypogonadism in men over 65. They reliably raise testosterone but suppress the HPG axis, causing testicular atrophy and azoospermia within 3 to 6 months. TRAVERSE confirmed non-inferior cardiovascular safety but found higher pulmonary embolism and atrial fibrillation rates [10]. Exogenous TRT remains the standard of care when fertility is not a concern and rapid symptom relief is needed.

Enclomiphene preserves testicular function, avoids the application burden of daily gels, and may be preferred in men who cannot use transdermal testosterone due to skin conditions or partner transfer risk. The trade-off is slower titration, less predictable response in older men with blunted HPG function, and a complete absence of geriatric-specific safety data.

vs. Clomiphene Citrate

Generic clomiphene citrate is the most commonly prescribed SERM for off-label male hypogonadism. It costs significantly less than compounded enclomiphene. Its main liability is the estrogenic load from the zuclomiphene fraction, which accumulates to higher levels in older men with slower hepatic clearance. Men over 65 who experience gynecomastia, mood changes, or persistently elevated estradiol on clomiphene may respond better to enclomiphene due to its cleaner receptor profile [3].

vs. HCG Monotherapy

Human chorionic gonadotropin (hCG) acts directly on testicular LH receptors, bypassing the hypothalamus and pituitary. It also preserves testicular size and fertility. In older men with pituitary or hypothalamic insufficiency, hCG may be more effective than enclomiphene, which requires an intact pituitary response to generate LH and FSH. When LH is already appropriately elevated relative to low testosterone (primary hypogonadism), neither enclomiphene nor hCG is an appropriate choice; exogenous testosterone is indicated.

Patient Selection: Who Is the Right Older Candidate?

Not every older man with low testosterone is an appropriate candidate for enclomiphene. The following criteria identify the subset most likely to benefit:

1. Morning total testosterone confirmed below 300 ng/dL on two separate measurements drawn between 7 and 10 a.m., at least one week apart, per Endocrine Society criteria [13].
2. LH and FSH that are low or inappropriately normal (indicating central suppression rather than primary testicular failure). Elevated LH and FSH in the setting of low testosterone indicates primary hypogonadism; enclomiphene will not help.
3. Symptomatic hypogonadism meeting the threshold described in the Endocrine Society guideline (sexual dysfunction, fatigue, loss of muscle mass, or depressed mood without other explanation).
4. Absence of active prostate cancer, hematocrit above 50% at baseline, untreated severe sleep apnea, or history of thromboembolic disease.
5. No current use of strong CYP3A4 inhibitors that cannot be substituted.
6. Willingness to monitor labs every 3 months for at least the first year.

Men with primary hypogonadism, severe pituitary pathology, or baseline hematocrit above 50 percent are not candidates.

Regulatory and Prescribing Considerations

Enclomiphene citrate has no FDA-approved NDA. Prescriptions are filled through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [15]. The FDA's 2023 guidance on compounded drug products reminds prescribers that compounded formulations have not undergone FDA pre-market review for safety, efficacy, or manufacturing quality. Clinicians should use only 503A or 503B-accredited facilities and document the clinical rationale for the off-label, compounded prescription in the medical record.

Prescribing off-label to men over 65 carries heightened informed-consent obligations. The patient should understand: (a) no clinical trial has specifically evaluated this drug in adults over 65; (b) testosterone-raising therapy in this age group carries cardiovascular signals documented in TRAVERSE; (c) response may be incomplete if HPG axis reserve is limited by age.